16

General Information


DRACP ID  DRACP04813

Peptide Name   16

Sequence  YRXG

Sequence Length  4

UniProt ID  Not available

PubChem CID  Not available

Origin  Synthetic

Type  Synthetic peptide

Classification

  

Active ACP



Activity Information


Hemolytic Activity  Not available

Normal (non-cancerous) Cytotoxicity  Not available

Target  Not available

Affinity  Not available

Mechanism  Not available

Nature  Anticancer



Structure Information


PDB ID  Not available

Predicted Structure  Not available

Helicity  Not available

Linear/Cyclic 

Disulfide/Other Bond  Native peptide

N-terminal Modification  Free

C-terminal Modification  Free

Other Modification  X=Cα -dialkylated glycine (Aaa2,2 )

Chiral  L



Physicochemical Information


Formula  C17H24N6O4

Absent amino acids  ACDEFHIKLMNPQSTVW

Common amino acids  GRYX

Mass  54010

Pl  9.35

Basic residues  1

Acidic residues  0

Hydrophobic residues  0

Net charge  1

Boman Index  -1412

Hydrophobicity  -155

Aliphatic Index  0

Half Life 
  /

Extinction Coefficient cystines  1490

Absorbance 280nm  496.67

Polar residues  2

Amino acid distribution



Literature Information


Literature 1

Pubmed ID 16722632

Title  Not available

Doi Not available

Year  Not available

Patent

Patent ID Not available

Patent Title  Not available

Other Iinformation  Not available

Other Published ID  Not available




CancerPPD ID  3942

CancerPPD ID  3943

CancerPPD ID  3944

CancerPPD ID  3945

CancerPPD ID  3946

CancerPPD ID  3947

CancerPPD ID  3948

CancerPPD ID  3949

CancerPPD ID  3950

CancerPPD ID  3951

CancerPPD ID  3952

CancerPPD ID  3953

CancerPPD ID  3954

CancerPPD ID  3955

CancerPPD ID  3956

CancerPPD ID  3957

CancerPPD ID  3958

CancerPPD ID  3959

CancerPPD ID  3960

CancerPPD ID  3961

CancerPPD ID  3962

CancerPPD ID  3963

CancerPPD ID  3964

CancerPPD ID  3965

DRACP is developed by Dr.Zheng's team.